<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Mathieu Gand</style></author><author><style face="normal" font="default" size="100%">Adelheid Soubry</style></author><author><style face="normal" font="default" size="100%">Birgit Mertens</style></author><author><style face="normal" font="default" size="100%">Nancy Roosens</style></author><author><style face="normal" font="default" size="100%">Sigrid C.J. De Keersmaecker</style></author></authors></contributors><titles><title><style face="normal" font="default" size="100%">Genetic and epigenetic biomarkers in human biomonitoring: why needed and how can Oxford Nanopore sequencing contribute?</style></title><secondary-title><style face="normal" font="default" size="100%">Frontiers in Public Health</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">DNA-methylation</style></keyword><keyword><style  face="normal" font="default" size="100%">effect biomarker</style></keyword><keyword><style  face="normal" font="default" size="100%">Human biomonitoring</style></keyword><keyword><style  face="normal" font="default" size="100%">large-population study</style></keyword><keyword><style  face="normal" font="default" size="100%">Oxford Nanopore Technologies</style></keyword><keyword><style  face="normal" font="default" size="100%">SNP</style></keyword><keyword><style  face="normal" font="default" size="100%">susceptibility biomarker</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2025</style></year><pub-dates><date><style  face="normal" font="default" size="100%">Jan-07-2025</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">13</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;Chemical risk assessment can benefit from integrating informative biomarkers in human biomonitoring (HBM). Beyond exposure biomarkers, effect biomarkers inform on biological reactions in the body, potentially leading to adverse effects, while susceptibility biomarkers address inter-individual variability in exposure. DNA methylation of key genes shows promise as an effect biomarker but this epigenetic mark remains underexplored in the context of chemicals. Similarly, although some genetic polymorphisms are linked to increased chemical susceptibility, genetic biomarkers are rarely included in HBM. This mini-review highlights recent literature supporting the inclusion of genetic and epigenetic biomarkers in HBM. Subsequently, we elaborate on how Oxford Nanopore Technologies as sequencing method can efficiently measure these biomarkers simultaneously, even in non-invasive samples like saliva. Widely used in other fields, this experimental set-up could facilitate the design of large-population studies paving the way for a next generation risk assessment (NGRA) of chemicals.&lt;/p&gt;
</style></abstract></record></records></xml>